Publication Name	World Journal of Gastroenterology
Manuscript ID	72834
Country	United States

Received	2021-10-30 05:31
Peer-Review Started	2021-10-30 05:33
To Make the First Decision
Return for Revision	2021-12-12 05:57
Revised	2022-01-17 23:40
Second Decision	2022-02-24 06:10
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-02-27 23:16
Articles in Press	2022-02-27 23:16
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-03-23 11:36
Publish the Manuscript Online	2022-03-30 15:20

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place
Manuscript Source	Invited Manuscript
All Author List	Brindusa Truta
ORCID	Author(s) ORCID Number Brindusa Truta http://orcid.org/0000-0003-4319-9278
Funding Agency and Grant Number
Corresponding Author	Brindusa Truta, MD, Assistant Professor, Internal Medicine, Johns Hopkins University, 1830 E Monument Street, Room 426, Baltimore, MD 21210, United States. brindusa_73@yahoo.com
Key Words	Therapeutic drug monitoring; Inflammatory bowel disease; Biologics; Crohn’s disease
Core Tip	While reactive therapeutic drug monitoring (TDM) was embraced in clinical practice as an important tool for assessing lack of response to biologics, existent evidence inconsistently supports the proactive use of TDM in managing inflammatory bowel disease (IBD) therapy. Exceptions are made for patients with severe ulcerative colitis and perianal Crohn’s disease (fistula) for whom TDM has consistently shown to improve clinical outcome, pregnant women with IBD for whom TDM has the potential to play a decisive role in withholding therapy and for children, for whom proactive TDM was found to increase steroid free clinical remission. Future studies are needed to define the real value of TDM in management of IBD.
Publish Date	2022-03-30 15:20
Citation	Truta B. Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place. World J Gastroenterol 2022; 28(13): 1380-1383
URL	https://www.wjgnet.com/1007-9327/full/v28/i13/1380.htm
DOI	https://dx.doi.org/10.3748/wjg.v28.i13.1380

Full Article (PDF)	WJG-28-1380.pdf
Full Article (Word)	WJG-28-1380.docx
Manuscript File	72834_Auto_Edited.docx
Answering Reviewers	72834-Answering reviewers.pdf
Audio Core Tip	72834-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	72834-Conflict-of-interest statement.pdf
Copyright License Agreement	72834-Copyright license agreement.pdf
Peer-review Report	72834-Peer-review(s).pdf
Scientific Misconduct Check	72834-Bing-Fan JR-2.png
Scientific Editor Work List	72834-Scientific editor work list.pdf
CrossCheck Report	72834-CrossCheck report.pdf
CrossCheck Report	72834-CrossCheck.png